SINGAPORE and SEOUL, South Korea, Oct. 9, 2024 /PRNewswire/ -- Hyundai Motor Group (the Group) has signed a collaborative research agreement with Nanyang Technological University, Singapore (NTU) in the field of new energy at the Singapore-Korea Business Forum, Ritz Carlton Singapore, on October 8. The partnership encompasses a three-year research collaboration, focusing on the hydrogen energy business and advanced energy system.
This collaboration between the Group and NTU, a globally renowned university, aims to develop alternative energy sources to achieve carbon neutrality, leveraging the Group's advanced energy technologies that are suitable for Singapore's unique characteristics.
"HMGICS is a global hub for Hyundai Motor Group's future mobility innovation," said Hyun Sung Park, Vice President and CEO of Hyundai Motor Group Innovation Center Singapore (HMGICS). "Through this partnership, we aim to accelerate our research in the field of innovative technologies, ultimately enhancing the commercial viability of our sustainable mobility solutions."
One of the key areas of focus will be studying the adoption of hydrogen production technologies and businesses in Singapore. This includes the implementation of Hyundai Motor Group's innovative resource-cycle hydrogen production technologies: Plastic-to-Hydrogen (P2H) and Waste-to-Hydrogen (W2H) systems. W2H utilizes organic waste such as food and sewage sludge to produce hydrogen, while P2H utilizes non-recyclable plastic.
In the field of advanced energy system research, the Group and NTU will develop a solution that is well-suited for urban countries like Singapore. The system offers the advantages of easy installation and high safety levels thanks to its modular design, playing a vital role in achieving carbon neutrality in Singapore.
HMGICS also held a joint signing ceremony for the establishment of a tripartite research center with NTU and the Agency for Science, Technology, and Research (A*STAR). The Corporate Lab Program is set to conduct research in innovative manufacturing domains such as AI, robotics and 3D printing.
"The research partnerships between NTU Singapore and Hyundai Motor Group reflect how close collaboration with industry is vital in developing innovative and relevant solutions to address real world issues, including the race to carbon neutrality," said Professor Lam Khin Yong, Vice President (Industry) of NTU. "We will continue to build on our long-standing partnership with Hyundai Motor Group, leveraging NTU's core strengths in areas such as sustainable energy, AI, robotics, 3D printing, and advanced materials, to develop innovative and sustainable solutions for Singapore and the global society."
For more information, please visit: http://www.hyundaimotorgroup.com or Newsroom: Media Hub by Hyundai, Kia Global Media Center (kianewscenter.com), Genesis Newsroom
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
Hyundai Motor Group and Singapore Strengthen Joint Research in Sustainable Energy and Manufacturing Solutions
Hyundai Motor Group and Singapore Strengthen Joint Research in Sustainable Energy and Manufacturing Solutions
KYOTO, Japan, Oct. 9, 2024 /PRNewswire/ -- Rege Nephro Co., Ltd. (https://www.regenephro.co.jp/) is excited to announce that the company has successfully developed a funding plan of total approximately 17 million dollar (2.5 billion JPY) in new Series B funding and raised 15 million dollar with the first payment. This significant investment brings the company's total funding to 30 million dollar. The funding round attracted a mix of strategic investors, including DCI Partners Co., Ltd. as a lead investor, JIC Venture Growth Investments Co., Ltd., Nippon Venture Capital CO., Ltd., TOHOKU University Venture Partners Co., Ltd., Golden Asia Fund Ventures Ltd., Mitsui Chemicals, Inc., Global Brain Corporation, Kyoto University Innovation Capital Co., Ltd., JAFCO Group Co., Ltd., Mitsubishi UFJ Capital Co., Ltd., ASAHI KASEI CORPORATION, QB Capital, LLC who recognize the potential of Rege Nephro in delivering new treatments to patients suffering from their diseases. The newly acquired funds will be strategically used to advance the clinical trials of RN-014, our promising treatment in Phase II trials for Autosomal Dominant Polycystic Kidney Disease (ADPKD), and to prepare for clinical trials in the United States. Additionally, the funding will support the completion of preclinical trials for our second innovative product, RN-032, aimed at treating Chronic Kidney Disease (CKD) through cell therapy.
Investor Statements
DCI Partners Co., Ltd.
"We are excited to announce that we are the lead investor in this round of investment from our fund. We are fully committed to supporting the growth of Rege Nephro."
JIC Venture Growth Investments Co., Ltd.
"We strongly believe that his advanced drug discovery research based on Professor Osafune's discoveries will provide new therapeutic solutions for intractable renal diseases."
Kyoto University Innovation Capital Co., Ltd.
"We are delighted that Rege Nephro, which we have supported since before the company was founded, has finally entered the clinical stage. We hope that this funding will accelerate the clinical trials and bring a new therapeutic drug to patients as soon as possible."
JAFCO Group Co., Ltd.
"We hope that this financing will further accelerate Rege Nephro research and development in iPS drug discovery and provide new treatment options for patients suffering from diseases with limited treatment options."
Mitsubishi UFJ Capital Co., Ltd.
"Our continued investment reflects our confidence in Rege Nephro's rapid progress and the potential of Professor Osafune's iPS cell technology to significantly impact medical practice."
Series B investors
DCI Partners Co., Ltd.
JIC Venture Growth Investments Co.,
Nippon Venture Capital CO., Ltd
TOHOKU University Venture Partners Co., Ltd.
Golden Asia Fund Ventures Ltd.
Mitsui Chemicals, Inc.
Global Brain Corporation
Kyoto University Innovation Capital Co., Ltd.
JAFCO Group Co., Ltd.
Mitsubishi UFJ Capital Co., Ltd.
QB Capital, LLC
Industrial Technology Investment
SHIMADZU CORPORATION
SCREEN Holdings Co., Ltd.
Chushin Venture Capital Co.,Ltd.
SENSHU IKEDA CAPITAL CO.,LTD.
Toyo Seikan Group Holdings, Ltd.
ASAHI KASEI CORPORATION
i-Lab CVC1 Limited Liability Partnership
Others
About Rege Nephro Co., Ltd.
Rege Nephro Co., Ltd. is a clinical-stage biotech company utilizing induced pluripotent stem cell (iPSC)-based technology from the Center for iPS Cell Research and Application (CiRA), Kyoto University. It is developing therapeutics and cell therapy for kidney, liver, and pancreas diseases.
About RN-014
Tamibarotene, under development for ADPKD, is a retinoic acid receptor (RAR) agonist expected to potently inhibit cyst formation and improve renal function. The Phase II clinical trial began in December 2023. This trial includes a pharmacokinetic (PK) phase and a randomization phase. Various safety measures have been established, including phased patient enrollment, periodic independent safety monitoring, strict criteria for dose reduction and discontinuation of the investigational drug, and criteria for discontinuation of the entire trial. There have been no significant issues at this time.
About RN-032
Cell therapy using NPCs for Chronic Kidney Disease (CKD). Nephron progenitor cells (NPCs) are cells that give rise to nephrons. Rege Nephro has been tried implanting iNPCs (NPCs induced from allogeneic human iPSCs) into the damaged kidneys, and the improvements in renal function have been confirmed in the several mouse experiments.
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
Rege Nephro Co., Ltd. Successfully Completes Series B Funding to Accelerate Kidney Disease Therapy Trials
